Show simple item record

dc.contributor.authorPerrotti, Danilo; orcid: 0000-0003-0726-8766
dc.contributor.authorAgarwal, Anupriya
dc.contributor.authorLucas, Claire M.
dc.contributor.authorNarla, Goutham; orcid: 0000-0003-4098-4203
dc.contributor.authorNeviani, Paolo
dc.contributor.authorOdero, Maria D.; orcid: 0000-0002-8858-2054
dc.contributor.authorRuvolo, Peter P.
dc.contributor.authorVerrills, Nicole M.; orcid: 0000-0002-7894-0137
dc.date.accessioned2021-10-30T00:39:14Z
dc.date.available2021-10-30T00:39:14Z
dc.date.issued2019-07-17
dc.identifierdoi: 10.1126/scitranslmed.aau0416
dc.identifier.citationScience Translational Medicine, volume 11, issue 501
dc.identifier.urihttp://hdl.handle.net/10034/626232
dc.descriptionFrom Crossref journal articles via Jisc Publications Router
dc.descriptionHistory: ppub 2019-07-17, issued 2019-07-17
dc.descriptionPublication status: Published
dc.descriptionFunder: National Cancer Institute; FundRef: 10.13039/100000054; Grant(s): CA163800
dc.descriptionFunder: National Cancer Institute; FundRef: 10.13039/100000054; Grant(s): CA209183
dc.publisherAmerican Association for the Advancement of Science (AAAS)
dc.sourcepissn: 1946-6234
dc.sourceeissn: 1946-6242
dc.subjectGeneral Medicine
dc.titleComment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”
dc.typearticle
dc.date.updated2021-10-30T00:39:14Z


This item appears in the following Collection(s)

Show simple item record